OpenAI is exploring innovative revenue models as the company seeks to fund its ambitious compute infrastructure plans and diversify beyond ChatGPT subscriptions. In a recent episode of “The OpenAI Podcast” published Monday, Chief Financial Officer Sarah Friar outlined potential new monetization strategies, including licensing models that would give OpenAI a share of downstream sales from successful customer products.
Friar presented a compelling example from the pharmaceutical sector: “Let’s say in drug discovery, if we licensed our technology, you have a breakthrough. The drug takes off, and we get a licensed portion of all its sales.” This revenue-sharing approach would create what Friar described as “great alignment” between OpenAI and its customers, ensuring both parties benefit from successful AI-powered innovations.
The CFO’s comments reveal how OpenAI’s business model has evolved significantly since ChatGPT’s launch. The company started with a single subscription tier but has since expanded to include multiple price points, SaaS-style enterprise pricing, and credit-based pricing for customers seeking premium access. This diversification reflects OpenAI’s need to support spending commitments estimated at $1.4 trillion over the coming years.
Last week, OpenAI announced plans to test advertisements in ChatGPT, marking a notable shift in strategy. CEO Sam Altman had previously called advertising a “last resort” during a May 2024 Harvard University event, stating that “ads plus AI is sort of uniquely unsettling to me.” However, his position has softened as the company’s compute costs have ballooned. By June, Altman acknowledged he wasn’t “totally against” advertising, though he emphasized careful implementation.
Friar addressed concerns about ads compromising ChatGPT’s integrity, stating that the model should “always give the best answer, not a sponsored one” and maintain an ad-free tier for users who prefer it. This approach aims to balance revenue generation with user trust and product quality.
The revenue exploration comes after OpenAI completed its restructuring in October, transitioning toward a more traditional for-profit structure. Altman indicated this change would facilitate capital raising efforts, essential for supporting the company’s massive infrastructure investments and continued AI research and development.
Key Quotes
Let’s say in drug discovery, if we licensed our technology, you have a breakthrough. The drug takes off, and we get a licensed portion of all its sales.
OpenAI CFO Sarah Friar outlined a potential licensing revenue model where OpenAI would receive a percentage of downstream sales from successful products built using their AI technology, creating aligned incentives between the company and its customers.
Ads plus AI is sort of uniquely unsettling to me. I kind of think of ads as a last resort for us for a business model.
CEO Sam Altman made this statement at Harvard University in May 2024, expressing strong reservations about advertising in AI products. His subsequent softening on this position highlights the financial pressures OpenAI faces with $1.4 trillion in spending commitments.
The model should always give the best answer, not a sponsored one, and maintain an ad-free tier.
Sarah Friar emphasized OpenAI’s commitment to maintaining ChatGPT’s integrity even as the company explores advertising, promising that sponsored content won’t compromise answer quality and that users will have ad-free options.
Our Take
OpenAI’s revenue diversification strategy reveals the uncomfortable truth about AI economics: even the industry leader with billions in funding cannot sustain current operations on subscriptions alone. The $1.4 trillion spending commitment is staggering and explains why previously “unsettling” options like advertising are now on the table. The licensing model Friar proposed is particularly intriguing—it could unlock AI adoption in risk-averse industries by aligning incentives, but implementation challenges are enormous. How do you quantify AI’s contribution to a drug discovery versus human researchers? What happens if the product fails? These questions will define the next phase of AI commercialization. The rapid evolution from Altman’s anti-ad stance to active testing demonstrates that AI companies’ idealistic visions are colliding with financial reality. This pragmatic shift may disappoint some users but reflects the massive infrastructure costs required to advance AI capabilities.
Why This Matters
OpenAI’s exploration of new revenue models represents a critical inflection point for the AI industry’s business sustainability. As the leading AI company faces unprecedented compute costs and infrastructure demands, its monetization strategies will likely set precedents for the entire sector. The shift from Altman’s “ads as last resort” stance to actively testing advertising demonstrates how even the most well-funded AI companies must grapple with economic realities.
The licensing model Friar proposed could fundamentally reshape AI-business partnerships, moving from simple software subscriptions to outcome-based revenue sharing. This approach could accelerate AI adoption in high-value sectors like pharmaceuticals, where breakthrough discoveries generate substantial returns. However, it also raises questions about risk allocation, intellectual property rights, and how to fairly attribute success to AI versus human innovation.
For businesses considering AI integration, these developments signal that AI pricing models will become increasingly sophisticated and varied, potentially offering more flexible arrangements but also greater complexity. The introduction of ads into ChatGPT, despite earlier resistance, underscores the immense financial pressure facing AI companies and suggests that user experiences may evolve as monetization intensifies across the industry.
Related Stories
- OpenAI Lost Nearly Half of Its AI Safety Team, Ex-Researcher Says
- OpenAI’s Competition Sparks Investor Anxiety Over Talent Retention at Microsoft, Meta, and Google
- Sam Altman and Jony Ive Partner on AI Device, Target $1B Funding
- Artificial Intelligence (AI) in Healthcare Market Outlook 2022 to 2028: Emerging Trends, Growth Opportunities, Revenue Analysis, Key Drivers and Restraints
- Elon Musk’s $97B OpenAI Bid: Strategic Move or Elaborate Troll?